This site is intended for Healthcare Professionals only.

GSK to buy Affinivax for up to $3.3 bln in vaccines push


Share post:

GlaxoSmithKline (GSk) on Tuesday (May 31) snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm.

The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax.

“GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc,” it said in a statement.

Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines,” it added.

The Cambridge, Massachusetts-based firm specializes in vaccines for diseases including meningitis, pneumonia and bloodstream infections.

“The proposed acquisition further strengthens our vaccines research and development (R&D) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area,” said GSK’s chief scientific officer Hal Barron.

“We look forward to working with the many talented people at Affinivax to combine our industry-leading development, manufacturing, and commercialization capabilities to make this exciting new technology available to those in need,” added Barron, who is also the group’s president of R&D.

The acquisitions come as chief executive Emma Walmsley seeks to reshape GSK after she faced fierce investor criticism over the company’s delay in producing Covid jabs and treatments.

Glaxo last month bought US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion.

GSK is meanwhile in the process of demerging its consumer health care arm Haleon — a joint venture with US peer Pfizer — to concentrate on its main pharmaceutical business.

Glaxo has been slammed by activist investors over its failure to swiftly produce a successful Covid vaccine, in stark contrast with Anglo-Swedish rival AstraZeneca.

The Affinivax purchase is expected to complete in the third quarter.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Medicine shortages: UK charities and pharmacists call for supply chain review

‘Unless there is openness and transparency between the government and manufacturers, resolving medicine shortages will remain impossible’ Health charities...

Europe Sees Surge in Generic Medicines Withdrawals; UK Faces Doubling of Drug Shortages

Generic medicines for cancer and mental health on the Union List of Critical Medicines are disappearing, study reveals...

NHS to support newly-trained pharmacists with new £1.5 million investment

The new initiative is set to create highly-skilled placement opportunities in community pharmacies, GP surgeries, and care homes...

Professor Mahendra Patel joins UK Pharmacy Professional Leadership Advisory Board

The nine independent expert members of the UK Pharmacy Professional Leadership Advisory Board announced   Professor Mahendra Patel OBE,...